Basic Information
NEBILET TABLET 5 mg
TABLET
Regulatory Information
SIN11728P
November 19, 2001
Prescription Only
Therapeutic
ORAL
August 10, 2023
June 3, 2025
XC07AB12
Company Information
A. MENARINI SINGAPORE PTE. LTD.
A. MENARINI SINGAPORE PTE. LTD.
Active Ingredients
Detailed Information
Contraindications
**Contraindications** - Hypersensitivity to the active substance or to any of the excipients. - Liver insufficiency or liver function impairment. - Pregnancy and lactation. - Acute heart failure, cardiogenic shock or episodes of heart failure decompensation requiring i.v. inotropic therapy. In addition, as with other beta-blocking agents, Nebilet is contra-indicated in: - sick sinus syndrome, including sino-atrial block. - second and third degree heart block (without a pacemaker). - history of bronchospasm and bronchial asthma. - untreated phaeochromocytoma. - metabolic acidosis. - bradycardia (heart rate < 60 bpm prior to start therapy). - hypotension (systolic blood pressure < 90 mmHg). - severe peripheral circulatory disturbances.
Indication Information
**THERAPEUTIC INDICATIONS** Hypertension Treatment of essential hypertension. Chronic heart failure (CHF) Treatment of stable mild and moderate chronic heart failure in addition to standard therapies in elderly patients > 70 years.